SYM 2081

Drug Profile

SYM 2081

Alternative Names: SYM-2081

Latest Information Update: 06 Nov 2006

Price : $50

At a glance

  • Originator Annovis
  • Class Analgesics
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 06 Nov 2006 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 18 Dec 2003 No development reported - Preclinical for Pain in USA (unspecified route)
  • 16 Apr 1997 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top